Metastatic Triple-Negative Breast Cancer | Virtual Case Library: Metastatic Triple-Negative Breast Cancer

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:

Introduction: Overview of metastatic triple-negative breast cancer (mTNBC)

• Current and emerging strategies for patients with mTNBC (0:00)

First-line treatment of mTNBC — Chemotherapy with or without immunotherapy

• Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10)
• Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41)
• Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15)

Antibody-drug conjugates (ADCs) in the management of mTNBC

• ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45)
• Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32)
• Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21)
• Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30)
• Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00)

PARP inhibition for the treatment of mTNBC

• Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49)
• Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28)
• Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11)
• Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45)

CME information and select publications